Medlab Clinical (Medlab Clinical) Interest Expense : $0.01 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Medlab Clinical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Medlab Clinical's interest expense for the six months ended in Dec. 2023 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Medlab Clinical's Operating Income for the six months ended in Dec. 2023 was $ -1.34 Mil. Medlab Clinical's Interest Expense for the six months ended in Dec. 2023 was $ -0.00 Mil. Medlab Clinical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Medlab Clinical Interest Expense Historical Data

The historical data trend for Medlab Clinical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical Interest Expense Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-0.06

-0.14

-0.04

-0.03

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial												-0.04	0.01	-0.01	0.01	-

Medlab Clinical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01 Mil.

Medlab Clinical (OTCPK:MDBBF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Medlab Clinical's Interest Expense for the six months ended in Dec. 2023 was $-0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was $-1.34 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was $0.00 Mil.

Medlab Clinical's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Medlab Clinical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Medlab Clinical (Medlab Clinical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (OTCPK:MDBBF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.